The prevailing assumption in AI development has been straightforward: larger models trained on more data produce better results. Nvidia's latest release directly challenges that size assumption — and ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion Pharmaceuticals announced positive Phase 1b/2 results from its ongoing TUPELO trial ...

Fintel reports that on December 17, 2025, JP Morgan upgraded their outlook for Recursion Pharmaceuticals (NasdaqGS:RXRX) from Neutral to Overweight. Analyst Price Forecast Suggests 37.89% Upside As of ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Add a description, image, and links to the javascript-2 topic page so that developers can more easily learn about it.

Chinese startup Beijing Moonshot AI Co. Ltd. Thursday released a new open-source artificial intelligence model, named Kimi 2 Thinking, that displays significantly upgraded tool use and agentic ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

Google Search seems to be testing dropping the ability to see 100 search results on a single page. When you add the results parameter to the end of your search results URL string, i.e. &num=100, it ...

Sept 2 (Reuters) - Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in ...